Aurora Cannabis Acquires Safari Flower in $26.5M Deal to Supercharge EU Medical Market

Aurora Cannabis Inc. announced on April 15, 2026 that it has closed an acquisition of Safari Flower Company, an EU GMP-certified cannabis cultivator and manufacturer, in a deal valued at $26.5 million. The transaction marks another step in Aurora's aggressive pivot from the saturated Canadian recreational market toward the higher-margin, rapidly expanding medical cannabis markets of Europe, Australia, and the United Kingdom.

Deal Terms at a Glance

The aggregate consideration of $26.5 million, subject to customary post-closing adjustments, includes a contingent $2 million cash payment tied to the satisfaction of certain conditions. On closing, Aurora issued the selling shareholder 2,417,180 common shares and paid $15 million in cash, subject to adjustment.

While the total purchase price is modest by cannabis M&A standards, the strategic significance is outsized. Safari Flower Company owns a purpose-built, 59,000 square foot EU GMP-certified indoor cultivation and manufacturing facility located in Ontario, Canada — adjacent geographically to Aurora's existing Canadian footprint but commercially tuned to serve high-margin European demand.

Why EU GMP Matters So Much

EU GMP, or European Union Good Manufacturing Practice, is the regulatory standard that cannabis products must meet to be sold in Germany, France, Italy, Poland, and most other European medical markets. Earning and maintaining EU GMP certification is expensive, slow, and technically demanding. Only a fraction of global cannabis producers hold it, which creates a structural supply constraint that benefits operators with certified capacity.

Germany — Europe's largest medical cannabis market — has grown dramatically since partial legalization in 2024, and patient numbers have continued climbing through 2026. With the UK, Australia, and Poland also expanding medical access, the demand for EU GMP-compliant flower and extracts has outpaced the supply available to international distributors.

Aurora's acquisition materially increases its EU GMP-certified cultivation capacity. According to the company, the incremental capacity will supply "Aurora's key international markets, including Germany, Australia, Poland, and the UK, and support further market expansion." Aurora expects the deal to contribute positive Adjusted EBITDA in fiscal year 2027, with incremental benefits in fiscal 2028 and beyond.

How This Fits Aurora's Global Strategy

Aurora has been publicly repositioning as a medical cannabis leader rather than a Canadian recreational player for years. Its current strategy emphasizes high-margin international medical markets where flower typically fetches several times the wholesale price of Canadian recreational cannabis. This acquisition is a direct investment in that thesis.

It also reinforces a broader consolidation trend among major cannabis operators:

• Organigram closed its acquisition of Berlin-based Sanity Group on April 15, 2026, the same day as the Aurora-Safari deal, gaining the number two market share position in Germany.
• Tilray Brands has continued to expand its European footprint through its Portugal and Germany operations.
• Curaleaf reorganized its European operations in 2025 and acquired a UK distributor to push deeper into Britain's medical market.

Taken together, these moves suggest the leading North American cannabis companies are treating Europe as the next primary growth engine, while the U.S. federal market remains blocked by Schedule I and the Canadian recreational market grapples with oversupply and price compression.

What It Means for Shareholders

For Aurora shareholders, the acquisition is a rare growth story in an otherwise challenging sector. Cannabis equities broadly have struggled in 2026 despite a December 2025 executive order from President Trump directing federal rescheduling. The DEA's rescheduling appeal process remains pending, leaving U.S. operators waiting for regulatory relief.

Aurora, which is not directly exposed to the U.S. federal market, has been able to focus on operational execution abroad. The Safari Flower acquisition is expected to be accretive to earnings, meaning it should add to — rather than dilute — Aurora's per-share financial metrics once integration is complete. That's a meaningful positive for a company that has spent most of the post-legalization era managing cash burn and impairment charges.

The deal also consolidates a supplier relationship. Safari Flower's facility has reportedly supplied Aurora's international pipeline on a wholesale basis prior to the acquisition. Owning the asset outright eliminates margin leakage to a third-party supplier and gives Aurora tighter control over quality, compliance, and expansion.

Risks and Open Questions

The deal is not without risk. Integrating a newly acquired cultivation site requires operational discipline, and Aurora has a mixed track record with prior acquisitions. EU GMP standards are also moving targets — regulatory scrutiny in Germany has tightened over the past two years, and future rule changes could require additional capital investment.

Aurora also faces foreign exchange exposure. Revenue generated in euros, British pounds, and Australian dollars can fluctuate against the Canadian dollar in which Aurora reports, introducing potential earnings volatility.

Finally, competition in EU medical cannabis is intensifying. More operators entering the market could compress the premium margins that make Europe attractive in the first place. Whether Aurora can maintain its pricing power as supply grows will determine how quickly the Safari Flower acquisition pays off.

Key Takeaways

• Aurora Cannabis closed its acquisition of Safari Flower Company for $26.5 million on April 15, 2026.
• The deal adds 59,000 square feet of EU GMP-certified cultivation capacity in Ontario, Canada.
• Aurora expects the transaction to contribute positive Adjusted EBITDA starting in fiscal year 2027.
• The acquisition supports Aurora's strategic pivot toward high-margin medical markets in Germany, the UK, Australia, and Poland.
• The deal arrives alongside Organigram's acquisition of Sanity Group, underscoring a broader consolidation trend among major North American cannabis operators pursuing European expansion.

Explore cannabis news, find dispensaries, and join the community at Budpedia.